|
KMID : 0380020200350030183
|
|
Korean Journal of Biotechnology and Bioengineering
2020 Volume.35 No. 3 p.183 ~ p.191
|
|
|
Chimeric Antigen Receptor-T cell (CAR-T) Therapy Targeting Hematologic Malignancy
|
|
Park Hyun-Mo
Kwon Mi-Ji
Lim Kwang-Suk
Park Hee-Ho
|
|
|
Abstract
|
|
|
|
Immunotherapy has demonstrated significant potential for the treatment of patients with hematologic malignancies and solid tumors. Among the many immunotherapy treatments, chimeric antigen receptor-T cell (CAR-T) therapy is the most promising treatment. The CAR-T cell is an effector T cell that recognizes and eliminates specific cancer cells, independent of major histocompatibility complex molecules. Currently, CAR-T therapy has many successful clinical results for hematologic malignancies. However, CAR-T has side effects and limits on anti-cancer effectiveness and persistence. Thus, a new CAR-T model is being developed to improve these problems. Although the new CAR-T model still needs more clinical trials, recent clinical trials have reported improvements over traditional CAR-T.
|
|
|
KEYWORD
|
|
|
immunotherapy, CAR-T therapy, hematologic malignancies, new CAR-T model, clinical trials
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|